Bio-Rad Laboratories (BIO) fundamentals: P/E, valuation, undervalued?
Bio-Rad Laboratories · Health Care · ref. ETF XLV · price $363.73
In short — Bio-Rad Laboratories trades at 46.1× earnings (P/E), 36.7× forward, with a net margin of 8.6 % and revenue growth of -0 %. Read: Fairly valued (P/E 37 in line with ~19% growth (PEG 2.0)).
Is Bio-Rad Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$363.73+19.2% over range
Oct 14, 25low $241.71 · high $390.34Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 3 analysts
Valuation : Fairly valued — P/E 37 in line with ~19% growth (PEG 2.0)
Valuation
46.1
P/E (price/earnings)
36.7
Forward P/E
2.47
PEG
1.4
Price/book (P/B)
$9.7B
Market cap
7.89
EPS
Profitability & growth
8.6 %
Net margin
-0 %
Revenue growth
+19 %
Earnings growth
$1.4B
Total debt
Bio-Rad Laboratories income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $2.8B | $-3.6B | -129.5 % |
| 2023 | $2.7B | $-637M | -23.9 % |
| 2024 | $2.6B | $-1.8B | -71.9 % |
| 2025 | $2.6B | $760M | 29.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Bio-Rad Laboratories's P/E and is the stock undervalued? What's a good P/E?
Bio-Rad Laboratories's P/E is 46.1 (forward 36.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Bio-Rad Laboratories profitable?
Bio-Rad Laboratories has a net margin of 8.6 % (EPS 7.89). The company is profitable.
Is BIO stock expensive?
Our read: "Fairly valued" — P/E 37 in line with ~19% growth (PEG 2.0). Cross-check with growth and sector.
💬 A question about Bio-Rad Laboratories? The JPI assistant answers using our backtest data.
Keep exploring Bio-Rad Laboratories